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1. Introduction
Platelets are especially well known for their thrombotic role. However, besides their role on
stopping bleeding, platelets contribute for several mechanisms and steps in wound healing
and tissue repair, such as inflammation, angiogenesis, cells proliferation, and differentiation.
The potential of platelets to be used therapeutically to assist in wound repair led researchers
around the world to look at platelet-based products and their capacity to promote tissue
regeneration, in vitro and in vivo. In this chapter, we will discuss the main growth factors
present in platelet granules that affect tissue regeneration. In addition, we will consider how
platelet-derived products, such as those obtained from platelet-rich plasma (PRP), can be used
to enhance tissue regeneration. We will review the applications of this knowledge in clinical
trials, and in vivo models, as well as discussing the capacity for platelet products to substitute
for classical components of media for in vitro cell culture.
2. Tissue repair related growth factors in platelets granules
Approximately, one trillion platelets circulate in the bloodstream of a human adult (4 liters of
blood at 3X108 platelets / ml). Platelets have a lifespan of approximately 10 days. They are
synthesized by megakaryocytic cells in the bone marrow of long bones and approximately
10% are replenished daily. “Old” and damaged platelets are cleared from the blood by
phagocytes in the liver and the spleen [1]. While in the circulation, platelets survey the
vasculature for evidence of damage. If damage is perceived, they participate in hemostatic
events. When platelets are activated upon vascular injury, they change their discoid form to a
more spherical morphology with pseudopods, and they release their granular content [2].
Those are not only related to the coagulation process and hemostasis, but also to tissue repair.
The granules are of 3 different types: α-granules, dense granules, and lysosymes. α-granules
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are the most abundant granule-type in human platelets (50-80 per platelet) and contain a
diverse protein repertoire [3] including a variety of molecules with biological activity (Table
1). These molecules are released following platelet activation and play important functional
roles at sites of vascular damage.
CATEGORY MOLECULE
GROWTH FACTORS
TGF-β (transforming growth factor beta)
PDGF (platelet-derived growth factor)
FGF (fibroblast growth factor)
EGF (epidermal growth fator)
VEGF (vascular endothelial growth factor)
ADHESION PROTEINS
Fibrinogen
Fibronectin
Vitronectin
Trombospondin-1
COAGULATION FACTORS
Factor V
Factor IX
Protein S
Anti-thrombin
FIBRINOLYTIC FATORS
Plasminogen
Plasminogen activatior inhibitor
α-2 antiplasmin
PROTEASES AND ANTIPROTEASES
TIMP-4(tissue inhibitor of metalloprotease-4)
Metaloprotease-4
α-1-antitripsin
MEMBRANE GLYCOPROTEINS CD40-LP-selectin
OTHER PROTEINS
PF-4 (platelet factor 4)
Endostatins
β-tromboglobulins
Table 1. Main bioactive molecules present in platelets alpha granules Adapted from [4].
Many platelet-derived bioactive proteins play critical roles in inflammation, angiogenesis and
wound  healing.  For  example,  TGF-β1,  the  most  abundant  isoform  of  TGF-β  present  in
platelets,  has  an  important  role  in  all  wound  healing  phases.  It  coordinates  multiple
pathophysiological events including the initial recruitment of inflammatory cells to a site of
injury, angiogenesis, re-epitheliazation following damage, and the induction of extracellu‐
lar matrix production by fibroblasts [5]. PDGF is a chemoattractant molecule for fibroblasts
and smooth muscle cells, as well as an inducer of proliferation of mesenchymal cells [6].
FGF-2,  the main FGF isoform present in platelets,  promotes angiogenesis  by supporting
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endothelial cell growth [7]. It is also a potent fibroblast mitogen and induces hyaluronic acid
synthesis to facilitate a scarless wound healing [8]. EGF enables mesenchymal cells prolifer‐
ation,  chemotaxis  and  cytoprotection  [9].  VEGF  is  a  pro-angiogenic  biomolecule  that
stimulates blood vessel formation [10], and expression of adhesion proteins that enhance
leukocyte adhesion [11]. In fact, a total of more than 300 bioactive agents have been identi‐
fied that are released from activated platelets [12]. These agents differ in their origin with
some components being synthesized in the parent megakaryocyte while others are scav‐
enged from plasma and concentrated in platelet granules [13].
Dense granules contain factors related to platelet activation, such as Ca2+ and ADP, serotonin,
histamine, dopamine, and catecolamines. Local release of these components, in response to
platelet activation or thrombotic events, results in altered recruitment of inflammatory cell
types and altered vascular permeability [14]. Finally, lysosomes contain hydrolytic enzymes
and catalases [15]. The nature of the contents of the platelet granules are summarised in
MItrugno et al (2015) in this publication.
Platelet activation, with concomitant release of granular contents, happens in parallel with
coagulation or thrombosis. The natural participation of platelets and in hemostasis and tissue
repair has led to the development of products that could help in those processes.
Due to the variety of possible uses and number of studies, PRP is perhaps the main platelet
based product investigated for tissue regeneration purposes. PRP is a platelet concentrate in
a small volume of plasma obtained after a centrifugal spin of whole blood to remove red cells
and while cells. Regular platelet concentration in peripheral blood is 150-350 x 106 per milliliter.
In the context of tissue engineering and wound repair, the term PRP refers to a platelet
concentration in plasma above this regular range, that can be injected into a wound site to
affect or accelerate repair. The clinical use of PRP, mainly in the cases of bone and soft tissue
regeneration, presents a platelet concentration of at least 109 per milliliter, which is around 5
times higher than physiological levels [16]. For peri-implant bone regeneration, for example,
the recommended platelet concentration is approximately 109 per milliliter. In lower concen‐
trations the effect is suboptimal and in higher it is inhibitory [17].
The therapeutic action of platelet concentrates derives from the release of factors involved in
tissue repair upon platelet activation. The clot that is formed during that activation may also
play a role of a temporary extracellular matrix which will allow cells proliferation and
differentiation [16]. In that case, an elevated platelet concentration would be expected to
generate an elevated local concentration of released bioactive factors. However the correlation
between the platelet concentration and the concentration of released bioactive agents may not
be exact, due to variations between blood donors [18], or between platelet preparation methods
[19]. Moreover, some growth factors that act in tissue repair are also present in plasma. Such
growth factors include HGF and IGF-1. Consequently, the concentrations of these factors at
sites of wounds may only be slightly altered according to the platelet concentration [20].
Generally, it is considered that a platelet concentration 5 times higher than in peripheral blood
can lead to an enhanced local concentration of growth factors that varies from 3 to 5 times in
excess of normal pathophysiological levels [4]. Thus, by serving as a reservoir of concentrated
growth factors involved in cell proliferation and differentiation, platelet concentrates can
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contribute to tissue growth and repair. In a similar manner, platelet-derived bioactive products
may find use in cell culture protocols.
3. How platelet products can improve cell culture
Since the beginning of cell culture techniques, many innovations were designed to optimize
the process of cell expansion in vitro, analyzing their differentiation capacity, as well as their
response to chemicals and promising pharmaceutical molecules. With time, the field im‐
proved. Plastics, glasses, bioreactors and engineering technology evolved a lot, at the same
time that the biological field also evolved.
Methods to grow cells in vitro try to reproduce appropriately all physiological conditions that
are observed in vivo, and try to mimic it in vitro. The culture medium is the source of soluble
factors that will enable cell growth and survival. Classical cell culture media are comprised of
a basal balanced salt solution such as MEM (Eagle's minimal essential medium), DMEM
(Dulbecco’s modified Eagle's medium), IMDM (Iscove’s modified DMEM), RPMI (Roswell
Park Memorial Institute medium), Medium-199, HamF12 and McCoy’s medium. Although
they provide inorganic salts, amino acids, vitamins and glucose, a protein-rich supplement is
required to provide growth factors. Traditionally, Fetal Bovine Serum (FBS) is added to the
basal medium [21] as the main source of growth factors to stimulate cell proliferation; FBS
contains transport proteins carrying hormones (e.g. transcortin), minerals, trace elements (e.g.
transferrin), and lipids (e.g. lipoproteins). In addition, FBS contain attachment and spreading
factors, acting as germination points for cell attachment; and stabilizing and detoxifying factors
needed to maintain pH or to inhibit proteases either directly, such as α-antitrypsin or α2-
macroglobulin, or indirectly, by acting as an unspecific sink for proteases and other (toxic)
molecules [22]. FBS is obtained by cardiac puncture of bovine fetuses without anaesthesia.
Jochems strongly discussed the ethical issues on the use of FBS. The use of cell culture is
strongly recommended as an alternative to animal experimentation. However, the require‐
ment for FBS, obtained from animal sources, end up making the concept of cell culture as an
alternative to animal experimentation somewhat unethical [23].
Besides the ethical issues, scientific issues are also pointed on the use of FBS. Firstly, lot-to-lot
variations make it necessary to test samples before purchase, as its molecular composition of
FBS may vary [24]. FBS might interfere with cells genotype and phenotype, influencing
experimental outcome. For example, it can promote cell proliferation in fibroblasts, whilst
inhibiting it in epithelial cells [25]. It can be contaminated with viruses, bacteria, mycoplasmas,
yeast, fungi, immunoglobulins, endotoxins, and possibly prions [26], contraindicating it for
use for cells that would be further transplanted into humans. FBS is not totally chemically
defined, as many substances present in it have not yet been characterized [27], some don’t have
their function fully elucidated, and others may even be toxic [28].
Serum, obtained from clotted whole blood, is known to be more suitable to cell culture than
plasma from the same organism; despite the difficulty in obtaining it in large quantities. This
is likely to be due to the release of proteins and growth factors from activated platelets during
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the clotting process [29], [30].Therefore, PRP, platelet lysates and other platelet-derived
products can substitute FBS in cell culture. As the platelets are present in an elevated concen‐
tration, the growth factors important for cell culture are also more concentrated, as already
discussed in this chapter. Finally, platelets can be easily obtained from human sources and
therefore better mimic the effects of serum in human cells. Thinking of cell therapy, it can be
used for growing cells that would be later transplanted into humans, especially when in an
autologous approach.
4. How platelets can be used to improve tissue repair
Platelet concentrates, with the concentration of 5 x1010 platelets / unit are usually used for the
treatment and prevention of severe hemorrhage [31]. The use of blood products for wound
closure and stimulation of repair, such as fibrin glues, was first described in the 1970s [32]. The
platelet gel emerged in the 1990s as a cheaper and autologous alternative compared to fibrin
glues [33]. In 1987, PRP emerged as a product of autologous transfusion after open heart
surgery, to prevent the need for a homologous product [34]. In 1998, Marx et al. described the
use of platelets as an accelerator of tissue repair/regeneration, in that case bone formation in
bone grafts for maxillofacial surgery [35].
Since then, most of the studies have shown an increase in bone repair, musculoskeletal tissues
(muscles, tendons, and cartilage) and other "soft” tissues when platelet concentrates are used
[36]. In the case of bone repair in maxillofacial surgery, the use of a platelet product efficacy
and safety have been proven. In that case, only 9 out of 1,287 maxillae and mandible short
implants (<8,5mm) from 661 patients between 2001 and 2008 had been lost. All implants had
been embedded in liquid PRGF (plasma-rich in growth fators). Briefly, PRGF is obtained by
centrifugation of whole blood collected in 9ml tubes containing sodium citrate at 580 x g for 8
minutes. Next, the 1ml fraction above red cell fraction is collected and activated with calcium
chloride [37]. Although platelet products lack osteoinductive factors as BMPs, they can
enhance bone formation. When PRP is added to human autogenous bone grafts, the bone
density is higher, higher the proportion of mature bone and lesser osteoclast resorption,
compared to size and age-matched grafts without PRP after 4 months of surgery [36]. Human
PRP with the presence of peripheral blood mononucleated cells had its angiogenic properties
proven in a nude animal model of critical size calvarial defect. Moreover, when it has been
used synergistically with BMP-2, the effect on bone healing was augmented, as observed by
histology, bone mineral density and bone mineral content after 8 weeks of implantation [38].
As said before, the induction of bone regeneration is more effective when PRP is used with
approximately 1 million platelets per microliter. This was shown in a study where femurs of
New Zealand white rabbits receiving an titanium implant where treated or not with autolo‐
gous PRP. Lower concentrations than 1 million platelets per microliter resulted in suboptimal
peri-implant bone formation, whereas higher concentrations caused an inhibitory effect [17].
In addition, mesenchymal cells treated with PRP are also able to promote better repair and
bone maturation in mandibular bone defects models, being pointed as an alternative to
autogenous grafts. This has been shown when bone defects of canine mandible were filled
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with autologous PRP gel, autologous PRP gel with bone-marrow MSCs or autogenous
particulate cancellous bone and marrow (PCBM). Briefly, PRP was obtained by 50mL blood
collection in heparin, followed by two centrifugation steps which resulted in platelet concen‐
tration 438% above baseline. PRP activation was performed by adding thrombin/calcium
solution. Increased bone formation and neovascularization was observed in the PRP plus MSC
group. [39].
In muscle injuries, some factors present in PRP such as IGF-1 and bFGF can accelerate tissue
repair. In contrast, TGF-β may lead to a fibrotic repair, increasing the possibility of the
recurrence of new lesions [40]. Although mice with muscular injuries have demonstrated
functional improvement when treated with high-frequency ultrasound-treated PRP, in order
to lyse platelets and release of growth factor [41]. A preliminary study on muscle strain injuries
in professional sportsman showed significant increase in the recovery time from injury when
treated with autologous conditioned serum (ACS). ACS was obtained by blood collection
without anti-coagulants followed by incubation and centrifugation for the retrieving of the
serum [42]. Nonetheless, the action of PRP in muscle injuries still requires further investigation
[43]. The first double-blinded, randomized, placebo controlled PRP clinical study on acute
muscle injury, did not confirm the benefits for the use of PRP to enable the return to sports
activities by athletes. In this case, PRP was prepared using a commercially available system
(Arthrex double syringe ACP system) according to the manufacturer’s instructions, and
apparently was not activated prior to injection [44]. However, the methodology used in this
work has been questioned, due to delayed administration and low dosage of PRP injections.
The authors replied that there is no consensus on time of PRP injections, as well as that their
PRP preparation method was in accordance with the literature [45].
Animal studies [46], [47] and human trials in tendon injuries show positive results through
the use of PRP [48]–[50]. Although clinical trials with appropriate methodologies have not
yet proven the effectiveness of PRP in this type of injury [51], localized platelet delivery can
induce mobilization of circulating cells to sites of rat tendon injuries with concomitant in‐
crease in collagen synthesis [52]. In vitro, platelets can induce proliferation, collagen synthe‐
sis [53] and release of angiogenic factors in human tenocytes [54].A systematic review stated
there were strong evidence against PRP injection for chronic lateral epicondylar tendinop‐
athy. In a total of 6 studies, 5 showed no significant benefit at the final follow-up, while 1
presented benefits for PRP injections compared to corticosteroid injection [55]. However, the
results presented in that review have been questioned [56]. Surprisingly, another systematic
review, selecting 9 studies, concluded there was limited but evolving evidence to support
PRP injections in lateral epicondylitis, suggesting that further studies regarding the prepara‐
tion of PRP as well as the timing of the interventions are needed [57].
Cartilage, as an avascular tissue, and so injuries are usually critical and difficult to repair.
Consequently, there is a need for new regenerative methods to address the specific demands
imposed by cartilaginous injuries [58]. In 2003, PRGF was first used in a case of cartilaginous
avulsion in a football player, causing an accelerated and rapid repair, which enabled the
athlete’s earlier return to sport activities [59]. Intra-articular PRP injections in patients with
chronic cartilage degeneration also demonstrated positive results evaluated by clinical score
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methods as IKDC and EQ-VAS. In those studies, PRP was prepared by two-centrifugation
steps which increased platelet concentration of 600% comparing to whole blood counting, and
was activated by calcium solution prior to injection [60], [61]. On the other hand, in vitro
analyses on chondrocytes proliferation and chondrogenic induction generated controversial
results in the literature: In general, PRP induced chondrocyte proliferation [62]. Regarding
chondrogenic induction, PRP appeared as an inducer [63], [64], while contradictory results
showing the promotion of fibrogenic phenotype have also been observed [65], [66]. These
antitheses may be related to different methodologies for PRP production, and therefore
requires a better assessment of the PRP effect on chondrogenic cells.
PRP has also shown to induce mesenchymal stem cells (MSCs) proliferation. Regarding
induction of osteogenesis on MSCs, mouse MSCs were treated with activated by thrombin/
calcium solution human PRP or washed platelets (WPLT), where the platelets had been
suspended in phosphate saline rather than plasma, with equal platelets concentration, 4 times
above the baseline. Interestingly, both stimulated cells proliferation in earlier time points,
while WPLT induced higher proliferation than PRP in later time points. Alternatively, ALP
activity and collagen type I expression, those indicatives of osteogenic differentiation, were
increased in PRP rather than WPLT [67]. In others studies, PRP gel could induce osteocalcin
and collagen type 1 expression in rat MSC [68], as well as activated PRP, with platelet con‐
centration 4 times higher the baseline, induced greater human MSC mineralization [69].
Interestingly, when the growth factors present in PRP are released in a controlled manner,
through the association of PRP with alginate hydrogel, human MSCs alkaline phosphatase
activity is induced [70]. As for chondrogenic induction in vitro, mRNA levels for aggrecan,
Sox-9, and Runx2 were increased in buffered, i.e. inactivated, PRP treated human MSCs [71].
Subchondral bone MSCs cultured in a 3D model also showed chondrogenic potential induced
by PRP (activated by freezing and thawing process), but not osteogenic or adipogenic [72].
Moreover, PRP associated with MSCs was able to induce chondrogenesis in vitro and in vivo
in full-thickness rabbit articular cartilage injury model [73]. Recently, a systematic review
selected 27 articles analyzing the role of PRP on MSCs in vitro proliferation and differentiation,
in comparison to FBS. It has been seen that PRP stimulates cells proliferation, preserves their
immunomodulatory capacity and may delay the acquirement of a senescent phenotype. The
majority of the studies also showed that PRP maintains cells adipogenic, osteogenic and
chondrogenic differentiation capacity, in fewer cases enhanced it, while in rare cases dimin‐
ished the adipogenic differentiation capacity [74].
Platelets have been shown to play an important role in the repair of many different tissues
such as skin [75], nervous tissue [76], corneal [77], myocardial [78], and vascular [79]. In
addition, platelet-derived products demonstrate distinct antimicrobial effects [80], and
contribute to orthopedic repair [81] and plastic surgery applications [82]. It is worth noting the
potential for therapeutic effects in sports medicine, as the need for elite athletes to recover
quickly from injuries and achieve their regular level of efficiency is huge. PRP use is currently
allowed by the global anti-doping agency [83].
There have been no reports of serious health problems arising after the therapeutic use of PRP
so far, but despite evidence demonstrating its positive effects, especially in repair of muscu‐
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loskeletal injuries, there are few published clinical studies, and even smaller the number of
works with sufficient methodological quality to ensure evidence-based decision-making use
of PRP [43]. Likewise, there is still a need for basic studies to better understand some still open
issues, such as the optimal concentration of platelets, the harm or the benefits of the presence
of leukocytes, a possible combination of recombinant proteins with PRP [15] and analysis of
its action at the cellular level.
5. The need of standardization
Due to the variety of protocols, many classifications are used to characterize platelet prepara‐
tions for tissue engineering purposes. Many groups refer generically to platelets used in tissue
engineering applications as Platelet-Rich Plasma (PRP). However, this can cause confusion,
since many biomedical researchers use the PRP abbreviation to refer to a simple enrichment
by centrifugation of whole blood to remove red blood cells and leukocytes. Nonetheless, tissue
engineers have adopted the term PRP to refer to platelet concentrates that can be re-injected
to a site of tissue injury with or without modification or activation. Moreover, additional
acronyms are used to sub classify the platelet preparations used in tissue injury-studies.
Among these classifications, we can find: PDWHF (platelet derived wound healing factors)
[84], L- PRP (leukocyte and platelet - rich plasma) [85], PRFM (plasma rich fibrin matrix) [86],
PRGF (plasma rich in growth factors) [87], among others.
Likewise, the PRP gel preparation used in tissue engineering applications cannot be referred
to as a " fibrin glue”, as the clot formed in the PRP activation contain the same components
and at similar concentrations to that found in a native blood clot and consists primarily of
fibrin, fibronectin and vitronectin, besides the bioactive molecules. The fibrin glue is only
considered a concentrate of fibrinogen, which is polymerized by thrombin and calcium [16].
This platelet gel was originally used as a substitute to fibrin glue in oral and maxillofacial
surgery [33]. It was also used in cutaneous chronic wounds [88], including diabetic ulcers
[89],  degenerative  disorders  of  the  knee  [90],  gynecologic,  cardiac,  and general  surgical
procedures [91].
Various commercial systems for the preparation of autologous platelet products for local
injection into wound sites have been developed. Among the main ones are: SmartPrep ® 2APC
+TM (Harvest Technologies), Biomet GPS III ® (Biomet Manufacturing Corp.), Arthrex ACP
® (Arthrex Inc), Cascade ® platelet - rich fibrin matrix (Musculoskeletal Trasnplant Founda‐
tion), Cascade ® platelet - rich plasma therapy (Musculoskeletal Trasnplant Foundation), BTI
plasma rich in growth factors (PRGF) (Biotechnology Institute) and Magellan ® Autologous
Platelet Separator System (Arteriocyte) [92]. Despite such variety, the basic formulation of PRP
consists of primarily autologous blood collection in the presence of anticoagulants. After
collection, the blood is centrifuged once or twice in order to separate the plasma with platelets
from erythrocytes and leukocytes and concentrate them. After the second centrifugation, part
of the plasma is used to resuspend the platelet concentrate, formulating the final PRP. The
portion of the plasma that is not used in this ressupension is commonly described as platelet-
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poor plasma (PPP). The release of growth factors contained in platelets granules occurs
following activation of the PRP with exogenous thrombin, collagen, or calcium chloride,
forming a clot. Some methodologies also may use freeze-thawing cycles or sonication by ultra-
sound treatment in order to disrupt platelets membrane and release of the growth factors. In
other cases, platelets may not be activated at all. Calcium chloride is important to enable fibrin
polymerization and thrombin generation by the endogenous coagulation cascade. The final
product, i.e. the supernatant liquid without the clot, is actually a serum derived from PRP [4].
Both commercial and non-commercial forms may vary on the speed and number of centrifu‐
gation steps to concentrate the platelets, the usage or not of anticoagulant, the type of antico‐
agulant, the presence of leukocytes, which may release matrix metalloproteinase and reactive
oxygen species that can increase tissue damage, and the substance that will induce platelet
activation. In the end, these variations generate diversity in types, concentration and speed of
the release of growth factors, which may explain different results among papers [93]. In order
to normalize and standardize platelets products for tissue engineering purposes, mainly by
the platelet concentration, activation (whether it occurs or not an how), and presence of white
blood cells, some classification systems have been proposed [83], [94].In summary, platelets
act as reservoirs of growth factors and bioactive agents. The localized application of concen‐
trated preparations of these reagents from autologous platelet donations appears to facilitate
and accelerate wound healing and tissue repair. Some controversy exists as to the effectiveness
of this treatment. However, significant variations in the platelet preparations, mainly platelet
concentration and activation, may explain some or all of the variations.
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